Sector Expert: Dennis Hulme

Edison Investment Research

Dennis Hulme joined Edison's healthcare team in November 2014 after almost 10 years covering the healthcare and agriculture sectors as an analyst at BBY Stockbrokers. Previously, he worked as a research scientist with CSIRO and the University of Sydney. Dr. Hulme has a Ph.D. in veterinary science from the University of Sydney.



Recent Interviews

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology (5/11/16)
australiamedicine630

Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully.

Recent Quotes

"RGS' Phase I Progenza safety trial met its primary endpoint."

— Dennis Hulme, Edison Investment Research (5/31/17)
more >

"RGS' strategy is to partner its product opportunities for development and commercialisation, allowing it to focus on early-stage product development."

— Dennis Hulme, Edison Investment Research (5/18/17)
more >

"RGS' strategy is to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

— Dennis Hulme, Edison Investment Research (4/24/17)
more >

"In addition to RGS' deal for Progenza in Japan, it has partnered with a top-5 global animal health company for development of CryoShot Canine."

— Dennis Hulme, Edison Investment Research (3/23/17)
more >

"RGS will seek wider applications of Progenza beyond osteoarthritis."

— Dennis Hulme, Edison Investment Research (2/16/17)
more >

"Our valuation of RGS increases with the AGC cash and larger addressable market in Japan partly offset by longer timelines and revised assumptions for CryoShot and Kvax."

— Dennis Hulme, Edison Investment Research (1/27/17)
more >

"Cancer immunotherapy, including cancer vaccines such as RGS' RGSH4K, is a biotech hotspot."

— Dennis Hulme, Edison Investment Research (12/8/16)
more >

"RGS has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

— Dennis Hulme, Edison Investment Research (11/17/16)
more >



Due to permission requirements, not all quotes are shown.